For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of this treatment and Tafamidis meglumine represents a significant breakthrough . These innovative therapies stabilize the transthyretin protein, halting its destructive build-up and lessening the severity of the illness. Individuals are n